Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Cash loan till payday - payday loans UK.
Popular Articles

Younger Men With Advanced Prostate Cancer Have Shorter Survival Times
While young men with prostate cancer have a low risk of dying early, those with advanced forms of cancer do not live as long as older men with similar forms of the disease. That is the conclusion of a new study published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The paradoxical findings indicate that there may be biological differences between prostate cancers that develop in younger men and those that develop in older men, and that uncovering these differences may help tailor screening and treatment strategies for patients based on age.

Report Examines Zimbabwean Refugees In South Africa
According to a report released Tuesday by Medicins Sans Frontiers (MSF), "Zimbabweans continue to cross the border [into South Africa] every day, legally and illegally, in massive numbers as a matter of survival," AFP/Google.com reports (AFP/Google.com, 6/2). An estimated "three million Zimbabweans - about a quarter of the entire population" have fled "the economic collapse and human rights abuses at home, as well as a cholera outbreak that has infected about 100,000 people," according to the BBC, and the "inauguration in February of a fractious power-sharing government in Zimbabwe has not stemmed the flight" (BBC, 6/2).
News of the day
UCB's CIMZIA(R) (certolizumab Pegol) Approved By The U.S. FDA For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia®, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered.
Cardiovascular

Ventana's Promising New Anti-Obesity Patent

Ventana Biotech Inc ("Ventana")(PINK SHEETS:VNTA), a biotechnology company that is developing a appetite-suppressing chewing gum, released detailed information about its innovative Anti-Obesity Chewing Gum. The goal of Ventana"s Anti-Obesity Chewing Gum is to combat the growing global obesity epidemic while capturing a share of the multi-billion dollar market for anti-obesity drugs. How it works Ventana"s proprietary chewing gum contains an extract of hoodia gordonii and 2-hydroxyoleic acid. Hoodia gordonii is a leafless, cactus-like plant that grows naturally in Southern Africa that was historically used by native populations to suppress appetite when making long hunting trips in the Kalahari Desert. The plant has also been found to possess the ability to lower blood glucose levels, thereby also making it an attractive candidate for the treatment and prevention of diabetes. The active ingredients in the plant extracts are released into the patient"s blood stream, and trigger a hormonal response in the part of the brain (the hypothalamus) that tells the body it is "full", thereby suppressing the appetite of the obese patient. Because the plant extracts activate hormones that naturally exist in the body, there are no harmful side effects. The simple logic is that the Anti-Obesity Chewing Gum eliminates the feeling of "hunger", which in turn leads the patient to ingest less food, which in turn leads to weight loss. Obesity is a growing problem in developed nations, and is associated with increased mortality, Type 2 Diabetes, and heart disease. With Ventana"s proprietary Anti-Obesity Chewing Gum, users can safely control their appetites. Early indications show the Gum is able to reduce appetite by between 15 and 25 percent. Ventana continues to perfect this promising biotechnology and plans to eventually out-license it to Big Pharma companies. The royalty cash-flow from a successful anti-obesity drug is estimated at 1.5 - 1.7 billion Dollars. The outlook for anti-obesity treatments such as that of Ventana"s is promising, as the anti-obesity market continues to grow, while concurrently, the availability of successful patents is lacking. Morgan Stanley estimates the market for drugs combating Type 2 Diabetes (strongly correlated to obesity) to be in excess of $35 billion by 2012. Ventana Biotech Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009